This study is to evaluate performances and genotyping capabilities of four human 29 papilloma virus (HR-HPV) tests based on real-time polymerase chain reaction (PCR) 30 technology platforms compared with the cobas test. Discordant results were further 31 analyzed using INNO-LiPA HPV genotyping test, the gold standard laboratory test to 32 determine presence and type of HPV infection. Over 200 samples from Hospital patients 33 were collected and analyzed using five HR-HPV tests. Women with positive test results 34 were referred directly to colposcopy. If a positive result was returned, biopsies were 35 administered for pathological classification. Clinical performances and genotyping 36
INTRODUCTION
The experimental conditions for the five HR-HPV tests follow the guidelines provided 137 within the associated protocols. During each run, both positive and negative controls were 138 included to ensure proper PCR responses were not subjected to carry over contamination. 139 The resulting fluorescence from the reaction is then measured to determine whether HPV 140 is present in the sample.
141

INNO-LiPA HPV test 142
The INNO-LiPA HPV test is based on reverse line hybridization using SPF10 primers 143 (13). Part of the L1 region of the HPV genome is amplified by multiplex PCR, and 144 includes biotin-labeled primer which is denatured and hybridized to strip. It can identify 145 28 HPV types containing 15 HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 146 73 and 82), 3 probable HR-HPV (26, 53, 66) and 10 low-risk HPV (HPV6, 11, 26, 40 
